Literature DB >> 22419536

Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged 65 years and over: data from a therapeutic drug monitoring service, 1996-2010.

Sally Bowskill1, Lewis Couchman, James Hunter MacCabe, Robert James Flanagan.   

Abstract

OBJECTIVE: To investigate the effect of dose and other factors on plasma clozapine concentrations in patients aged 65 years and over.
METHOD: Audit of clozapine therapeutic drug monitoring data, 1996-2010.
RESULTS: There were 1930 samples [778 patients, 363 men aged (median, range) 67 (65-100) years and 415 women aged 68 (65-90) years]. There was no significant difference in the mean plasma clozapine concentration between men (0.56 mg/l) and women (0.58 mg/l), although the mean dose was higher in men (323 mg/d) than women (264 mg/d). The higher proportion of men (46%) compared with women (37%) smokers could explain this finding. Overall, 32% of samples had plasma clozapine below, and 37% above, a target range of 0.35-0.60 mg/l. Overall, the median dose decreased from 300 (65-70 years) to 200 mg/d (age 85 years and over). However, prescription of >350 mg/d was associated with a 50% likelihood that the plasma clozapine would exceed 0.60 mg/l. For a subgroup of 196 patients (114 men, 82 women), mean plasma clozapine was significantly higher after age 65 despite significantly lower dosage.
CONCLUSION: Clozapine dosage in elderly patients should be reviewed regularly to minimise the risk of adverse effects.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22419536     DOI: 10.1002/hup.2223

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  8 in total

Review 1.  Adverse effects of clozapine in older patients: epidemiology, prevention and management.

Authors:  Delia Bishara; David Taylor
Journal:  Drugs Aging       Date:  2014-01       Impact factor: 3.923

2.  Genetic and Clinical Factors Affecting Plasma Clozapine Concentration.

Authors:  Eric Olsson; Gunnar Edman; Leif Bertilsson; Dzana Sudic Hukic; Catharina Lavebratt; Sven V Eriksson; Urban Ösby
Journal:  Prim Care Companion CNS Disord       Date:  2015-02-19

3.  Dried Volumetric Microsampling Approaches for the Therapeutic Drug Monitoring of Psychiatric Patients Undergoing Clozapine Treatment.

Authors:  Camilla Marasca; Roberto Mandrioli; Roccaldo Sardella; Tomaž Vovk; Andrea Armirotti; Andrea Cavalli; Alessandro Serretti; Michele Protti; Laura Mercolini
Journal:  Front Psychiatry       Date:  2022-06-01       Impact factor: 5.435

4.  Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients.

Authors:  Helmi Ammar; Zohra Chadli; Ahmed Mhalla; Sabria Khouadja; Ibtissem Hannachi; Mohammed Alshaikheid; Ahlem Slama; Nadia Ben Fredj; Najeh Ben Fadhel; Haifa Ben Romdhane; Amel Chaabane; Naceur A Boughattas; Lotfi Gaha; Lazhar Zarrouk; Karim Aouam
Journal:  Pharmacogenomics J       Date:  2021-03-17       Impact factor: 3.550

5.  Population Pharmacokinetics of Clozapine: A Systematic Review.

Authors:  Orwa Albitar; Sabariah Noor Harun; Hadzliana Zainal; Baharudin Ibrahim; Siti Maisharah Sheikh Ghadzi
Journal:  Biomed Res Int       Date:  2020-01-07       Impact factor: 3.411

6.  Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals.

Authors:  R J Flanagan; J Lally; S Gee; R Lyon; S Every-Palmer
Journal:  Br Med Bull       Date:  2020-10-14       Impact factor: 4.291

7.  Changes in smoking status, mental state and plasma clozapine concentration: retrospective cohort evaluation.

Authors:  Inti Qurashi; Paul Stephenson; Chitra Nagaraj; Simon Chu; Richard Drake; Lewis Couchman; Robert Flanagan
Journal:  BJPsych Bull       Date:  2019-12

8.  Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations.

Authors:  Michaela Mayerova; Libor Ustohal; Jiri Jarkovsky; Jan Pivnicka; Tomas Kasparek; Eva Ceskova
Journal:  Neuropsychiatr Dis Treat       Date:  2018-06-14       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.